Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

Show other versions (1)

Bibliographic Details
Main Authors:	Roger H. Brookes, Philip C. Hill, Patrick K. Owiafe, Hannah B. Ibanga, David J. Jeffries, Simon A. Donkor, Helen A. Fletcher, Abdulrahman S. Hammond, Christian Lienhardt, Richard A. Adegbola, Helen McShane, Adrian V. S. Hill
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072427/?tool=EBI

Similar Items

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Roger H Brookes, et al.
Published: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
by: Roger H. Brookes, et al.
Published: (2011-01-01)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Kathryn T Whelan, et al.
Published: (2009-06-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
by: Gareth Betts, et al.
Published: (2012-01-01)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
by: Michele Tameris, et al.
Published: (2014-01-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
by: Anne Wajja, et al.
Published: (2017-05-01)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
by: Tandakha N Dieye, et al.
Published: (2013-01-01)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
by: Tandakha N. Dieye, et al.
Published: (2013-01-01)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
by: Tandakha N. Dieye, et al.
Published: (2013-01-01)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <i>M.tb</i>-Infected Adults
by: Michael Riste, et al.
Published: (2021-04-01)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
by: Kristin L Griffiths, et al.
Published: (2011-01-01)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
by: Sharon Sheehan, et al.
Published: (2015-01-01)

Cost-effectiveness analysis of MVA85 vaccine: a new TB vaccine candidate
by: Channing, Liezl
Published: (2014)

Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.
by: Magali Matsumiya, et al.
Published: (2013-01-01)

The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01E and MVA85A
by: Inayat Ullah, et al.
Published: (2020-10-01)

Correction: MVA.85A Boosting of BCG and an Attenuated, Deficient Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques.
by: Frank A. W. Verreck, et al.
Published: (2011-01-01)

IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
by: María Paula Morelli, et al.
Published: (2020-09-01)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
by: Patricia Pérez, et al.
Published: (2020-02-01)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
by: Zita-Rose Manjaly Thomas, et al.
Published: (2019-04-01)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
by: Eoghan de Barra, et al.
Published: (2014-01-01)

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
by: Frank A W Verreck, et al.
Published: (2009-01-01)

Correction: MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques
by: Frank A. W. Verreck, et al.
Published: (2011-01-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
by: Jeffrey R Currier, et al.
Published: (2010-11-01)

Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial.
by: Erick Wekesa Bunyasi, et al.
Published: (2015-01-01)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
by: Wyatt LS, et al.
Published: (2009-10-01)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Ansar A Pathan, et al.
Published: (2007-10-01)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Ansar A. Pathan, et al.
Published: (2011-01-01)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials.
by: Ansar A. Pathan, et al.
Published: (2011-01-01)

Measurement of human T-cell turnover following vaccination with the tuberculosis vaccine MVA85A
by: Porter, David William
Published: (2010)

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A [version 1; referees: 1 approved, 2 approved with reservations]
by: Anne Wajja, et al.
Published: (2018-09-01)

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
by: Juan García-Arriaza, et al.
Published: (2010-01-01)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
by: Angela M Minassian, et al.
Published: (2011-01-01)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Caroline Ogwang, et al.
Published: (2013-01-01)

Comparison of two interferon gamma release assays in the diagnosis of <it>Mycobacterium tuberculosis </it>infection and disease in The Gambia
by: Donkor Simon, et al.
Published: (2007-10-01)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
by: Hans de Graaf, et al.
Published: (2021-07-01)

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
by: Richard D Antrobus, et al.
Published: (2012-01-01)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
by: María Q. Marín, et al.
Published: (2020-08-01)

NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin
by: Stephanie L. Sanos, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_6p2cengup5foi6ttsb6cr9e54h